Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Homo sapiens | polymerase (DNA directed) iota | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.0049 | 0.0033 |
Echinococcus granulosus | calcium release activated calcium channel | 0.2214 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.003 | 0.0049 | 0.0049 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0023 | 0.0017 | 0.5 |
Schistosoma mansoni | Protein orai-1 | 0.2214 | 1 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.0049 | 0.5 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.0017 | 0.5 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0023 | 0.0017 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.003 | 0.0049 | 1 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0023 | 0.0017 | 0.5 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0023 | 0.0017 | 0.0017 |
Echinococcus multilocularis | calcium release activated calcium channel | 0.2214 | 1 | 1 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0023 | 0.0017 | 0.0017 |
Schistosoma mansoni | Protein orai-1 | 0.2214 | 1 | 1 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 0.0049 | 1 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0023 | 0.0017 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.0049 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.0049 | 0.5 |
Giardia lamblia | DINP protein human, muc B family | 0.0023 | 0.0017 | 0.5 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.003 | 0.0049 | 0.5 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0.0049 | 0.5 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.0017 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.2214 | 1 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.0049 | 1 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0023 | 0.0017 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.1042 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 3.9811 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | 10 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 44.6684 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.